|
|
Krystyna |
|
Nahlik, PhD |
|
Senior Field Application Scientist |
Clinical Genomics LGC Clinical Diagnostics |
https://proventainternational.com/wp-content/uploads/2022/06/Krystyna-Nahlik.jpg |
Krystyna has been working in the genomics industry for over 10 years and is the global lead for clinical genomics applications support at LGC Clinical Diagnostics. She holds a PhD from the University of Göttingen. |
|
|
Claudia |
|
Hesselmann, PhD |
|
Co-founder & CEO |
ARENSIA |
https://proventainternational.com/wp-content/uploads/2020/01/Claudia-Hesselmann-Arensia-Headshot-e1584469734743.png |
Claudia Hesselmann, PhD, a chemist by training, with a PhD in molecular biology. Claudia has twenty years of expertise in the early phases of drug development. Her experience includes co-founding and holding management positions in various CROs. Her extensive background and social acumen, along with her first-hand knowledge of the industry, led Claudia to co-found ARENSIA Exploratory Medicine in DĂĽsseldorf, Germany. Her primary aim is the contribution of innovative approaches to bring about substantial acceleration to the drug development process and enable more agile patient access to novel therapeutics. |
|
|
Mike |
|
Reed, PhD |
|
Chief Scientist, PhysioPD |
Rosa & Co. |
https://proventainternational.com/wp-content/uploads/2021/01/Mike-Reed-New.jpg |
Dr. Reed brings 15 years of experience managing large-scale strategic collaborations with client biopharmaceutical and consumer product organizations.
At Rosa (and previously at Entelos, Inc.), his areas of expertise include metabolic diseases, oncology, central nervous system diseases, and inflammation/immunology. His efforts focus on trial design, target evaluation, competitive differentiation, and novel biomarkers, and have led to several patents and publications. Dr. Reed’s work has been presented at dozens of scientific conferences worldwide.
Prior to his position at Entelos, Dr. Reed held positions in preclinical pharmacology and drug development at Shaman Pharmaceuticals Inc. and Tularik Inc. (acquired by Amgen Inc.). His contributions include the development of novel animal models for type 2 diabetes.
Dr. Reed completed his BS in Biology and MA in Exercise Physiology at The University of Texas at Austin, and a PhD in Exercise Physiology at The Ohio State University. He completed his postdoctoral fellowship at Stanford University, which focused on the mechanistic evaluation of insulin resistance in animal models. |
|
|
Barnaby |
|
Balmforth, PhD |
|
Chief Executive Officer |
Biofidelity |
https://proventainternational.com/wp-content/uploads/2022/03/Barnaby-Balmforth.jpg |
Barnaby has more than 10 years’ experience in the leadership of genomic technology development. Prior to co-founding Biofidelity he was Chief Operating Officer and Board member at Base4 as well as leading the development of the company’s molecular biology. Barnaby holds a PhD from the University of Cambridge and a Masters from the University of Oxford. |
|
|
Mahendra |
|
Deonarain |
|
CEO |
Antikor Biopharma |
https://proventainternational.com/wp-content/uploads/2022/01/Mahendra-Deonarain.jpeg |
Dr Deonarain studied at Imperial College and Cambridge University where he carried out PhD research into protein engineering. From 1997-2011 Dr Deonarain was a Principle Investigator at Imperial College in Antibody Technology, which led to some novel technologies being developed commercially. Dr Deonarain now retains honorary links. He has published over 80 papers and patents in protein/antibody engineering/conjugates. In 2014, he co-founded Antikor Biopharma where he is the CSO leading a team of 15 to develop the next-generation of antibody-fragment based ADCs. Dr Deonarain is also Antikor’s CEO, driving the commercial development of Antikor’s OptiLink platform to develop FDC products for therapeutic applications |
|
|
Hani |
|
Gabra |
|
Co-founder and CSO |
Papyrus Therapeutics |
https://proventainternational.com/wp-content/uploads/2022/03/Hani-Gabra-2.jpg |
Hani Gabra is Founder and CSO of Papyrus Therapeutics, a US based preclinical stage biotech company that is developing extracellular tumour suppressor therapies based on the OPCML tumour suppressor. He is also Emeritus Professor and Honorary NHS Consultant in Medical Oncology at Imperial College London and Adjunct Professor in Personalised Cancer Medicine at the Centre for cancer Biomarkers, University of Bergen, Norway. Previously he also held appointments of Chief Medical Officer, BerGenBio and Vice President in Early Cinical Development at AstraZeneca. |
|
|
Oliver |
|
Nussbaumer |
|
VP Immunology |
GammaDelta Therapeutics / Takeda |
https://proventainternational.com/wp-content/uploads/2022/01/Oliver-Nussbaumer.jpg |
Oliver Nussbaumer is an entrepreneur and scientific leader in the field of immunotherapy and founder of Gammadelta Therapeutics and Adaptate Biotherapeutics. Oliver has over 10 years proven track record in translational R&D, early process development and team building/leading teams in the field of immuno-oncology cell therapy. Having published multiple papers on the biology, potential and translation of human γδ T-cells, Oliver’s research enabled pioneering methods to isolate, expand and study human tissue resident γδ T-cells for clinical use, leading to over 10 international patent applications. In the past, Oliver’s work was supported by the Medical Research Council and recognised with Industry awards by Sanofi, the Austrian Ministry of Science and the Austrian Society of Immunology. Oliver joined GammaDelta Therapeutics full-time shortly after its incorporation as Head of Cell Research, responsible for process development. In early 2020, he was appointed as Vice President, Immunology and is now leading on early process development as well as research and discovery. |
|
|
Sonal |
|
Patel |
|
VP, Oncology Scientific Innovation |
Johnson & Johnson |
https://proventainternational.com/wp-content/uploads/2022/01/Sonal-Patel.jpeg |
Sonal joined Johnson & Johnson Innovation, London in 2016. As VP of Oncology Scientific Innovation, EMEA her role is to identify and champion the execution of transformative scientific opportunities for Janssen oncology. Before joining the Johnson and Johnson family, Sonal was Senior Director of External Innovation at Roche in Basel, Switzerland. She also was Head of Disease Biology in the Bioelectronic Medicines R&D unit of Glaxo SmithKline in Stevenage, UK. In both roles Sonal Led scientific diligence of new opportunities across therapeutic modalities including devices and led partnerships to develop a portfolio of external collaborations for pharma.
Sonal has had an extensive prior career in biotech in the UK as Head of Molecular Pharmacology at Prosidion-OSI, at a start-up company, Piramed on small molecule discovery for PI3K family and at Oxford Glycosciences, a proteomics platform company, leading target Identification and validation for oncology discovery projects.
Sonal completed postdoctoral training at the Lombardi Cancer Centre, Dept. of Radiation Medicine at Georgetown University |
|
|
Nahuel |
|
Villegas |
|
Chief Scientific Officer |
Vivan Therapeutics |
https://proventainternational.com/wp-content/uploads/2022/06/Nahuel-Villegas.jpg |
|
|
|
Mihriban |
|
Tuna |
|
Chief Scientific Officer |
Adaptate Biotherapeutics / Takeda |
https://proventainternational.com/wp-content/uploads/2022/01/Mihriban-Tuna.jpg |
Mihri has nearly 20 years’ experience in biologics drug discovery and development across biotech and pharma. She joined Adaptate from F-star where she was Senior Vice President of Drug Discovery, overseeing all internal and collaborative bispecific antibody programmes from concept through to candidate selection. Previously she held key scientific roles within antibody generation and technology development at Domantis and later in Biopharm R&D at GSK. She holds a PhD in Biochemistry from the University of Sussex and an executive MBA from the Judge Business School at the University of Cambridge. |
|
|
Achim Kaunert |
|
|
|
Senior Manager Business Development Central Europe |
Personalis |
https://proventainternational.com/wp-content/uploads/2022/06/Achim-Kaunert.jpg |
|
|
|
Mark |
|
Thornber |
|
Associate Director, Biopharma Business Development |
Personalis |
https://proventainternational.com/wp-content/uploads/2022/06/Mark-Thornber-New.jpg |
|
|
|
Govinda |
|
Bhisetti |
|
Vice President and Head of Computational Chemistry |
Cellarity |
https://proventainternational.com/wp-content/uploads/2020/08/Govinda-Bhisetti-1.jpg |
Govinda Bhisetti got his Ph.D. from the Indian I at Vertex Pharmaceuticals Inc. in 1990 and worked in the Computational Sciences department for 22+ yenstitute of Science, Bangalore, in 1986. He joined the Scripps Research Institute in La Jolla, CA, as a postdoctoral fellow in 1987. His work at Scripps involved the use of Cray XMP supercomputers to simulate protein-ligand interactions and design novel inhibitors. From there, he went to workars, where he led molecular modeling and drug design efforts on several drug discovery projects. His research at Vertex led to the discovery of three FDA- approved drugs: two AIDS drugs, Agenerase (amprenavir) and Lexiva (fosamprenavir), and one hepatitis C drug, Incivek (Telaprevir). He is a co-inventor of these drugs and has been named an inventor on 26 patents. He published 72 research papers, including review articles and book chapters. |
|
|
Achim Kaunert |
|
|
|
Senior Manager Business Development Central Europe |
Personalis |
https://proventainternational.com/wp-content/uploads/2022/06/Achim-Kaunert.jpg |
|
|
|
Mark |
|
Thornber |
|
Associate Director, Biopharma Business Development |
Personalis |
https://proventainternational.com/wp-content/uploads/2022/06/Mark-Thornber-New.jpg |
|
Radisson Blu Hotel, Stansted Airport
Payment Securely powered by stripe
